Sienabiotech to Implement ActivityBase for Lead Discovery Data Management

Guildford, UK and Siena, Italy, Jan. 12 — IDBS, provider of integrated data management, analysis and decision-making software for biopharmaceutical discovery research, announced today that Sienabiotech S.p.A. of Italy will implement IDBS’ ActivityBase suite. Sienabiotech is a research-based drug discovery company with particular expertise in CNS disorders, operating across the spectrum of discovery activities from target identification to phase IIa clinical trials. Sienabiotech will deploy ActivityBase in Lead Discovery to capture, manage and integrate biological, chemical and inventory data.

The company has chosen the ActivityBase Inventory Manager module (AIM) as part of its core data management system. Since AIM and ActivityBase use the same data model, inventory and screening workflows are closely integrated. AIM takes a somewhat less compound-centric approach than traditional inventory systems, enabling other samples, such as proteins and cells, to be managed with the same efficiency as compounds within the ActivityBase environment.

Georg C. Terstappen, Vice President of Discovery Research at Sienabiotech commented, “The ActivityBase suite will facilitate our ambitious plans as it provides a scalable platform for managing inventory, screening and cheminformatic data. Furthermore, it will facilitate data exchange between biologists and chemists across the organisation thus providing a solid basis for maximum knowledge extraction.” He continued: “Our evaluations revealed that ActivityBase has the edge, both in terms of functionality and ease of use.”

Neil Kipling, Chairman and CEO of IDBS said, “Sienabiotech is among a growing number of companies adopting an integrated strategy for managing inventory and lead discovery data. We are very pleased to be working with Sienabiotech, at the leading edge of neurodegenerative CNS disorders, helping them put in place an informatics foundation for sustainable growth.”

About Sienabiotech S.p.A
Sienabiotech S.p.A is an innovative biomedical research company situated in the heart of Tuscany in Italy. The company’s focus comprises studying diseases of the central nervous system including rare diseases with the aim of identifying validated drug targets and lead molecules for therapeutic intervention. In order to support the drug discovery process from exploratory target identification towards phase IIa clinical studies, the most advanced technology platforms including bioinformatics, proteomics, combinatorial chemistry, HTS and in vitro and in silico ADMET are being applied. Sienabiotech is owned by the Italian Monte dei Paschi di Siena foundation.

About IDBS
IDBS works with discovery organisations to maximise the value of research data, by providing software solutions to capture, manage and use biological and chemical information in an integrated framework. Unlike resource-intensive tool-based solutions, IDBS delivers complete – and proven – applications that bridge the gap between IT and science. Headquartered in Guildford, United Kingdom, IDBS has offices in Emeryville, California; Parsippany, New Jersey; and, Cambridge, Massachusetts. IDBS partners with CTC Laboratory Systems in Japan to market IDBS products and services. Founded in 1989, IDBS employs over 150 people worldwide.

About ActivityBase
ActivityBase from IDBS is an integrated data management software application used by nine of the ten largest pharmaceutical companies and many leading biotechnology firms. The software incorporates high-throughput and high-content screening, high throughput multiple IC50 determinations, lead optimisation, pharmacology, ADME, toxicology and DMPK studies, quantitative expression data handling and inventory, combined with the ability to register, manage and display chemical structures and reactions. Through the implementation of ActivityBase, scientists can easily define and run experiments, capture, visualise and analyse the information obtained and then share the data throughout the company and with collaborators to help streamline the discovery research process.

For further information, please contact:

Beth Thomas, Marketing Communications Manager
IDBS, 2 Occam Court, Surrey Research Park
Guildford, Surrey GU2 7QB, UK
Tel: +44 (0) 1483 595010
Fax: +44 (0) 1483 595001
Email: bthomas@id-bs.com

Gianluca Breghi, VP Finance and Business Development
Sienabiotech S.p.A
Tel: +39 0577 381 219
Email: gbreghi@sienabiotech.it